Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Kawahara, Rebeca ^a   Granato, Daniela C ^a   Carnielli, Carolina M ^a   Cervigne, Nilva K ^b   Oliveria, Carine E ^b   Martinez, César A R ^a   Yokoo, Sami ^a   Fonseca, Felipe P ^b   Lopes, Marcio ^b   Santos Silva, Alan R ^b   Graner, Edgard ^b   Coletta, Ricardo D ^b   Leme, Adriana Franco Paes ^a  

^a BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; CHONDROITIN SULFATE; CISPLATIN; N ACETYLGALACTOSAMINE 4 SULFATASE; PERLECAN; SCLEROPROTEIN; ANTINEOPLASTIC AGENT; PROTEOHEPARAN SULFATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; ENZYME MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; CELL MOTION; DRUG RESISTANCE; GENE EXPRESSION; GENE SILENCING; GENETICS; MOUTH TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

AGRIN; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MOUTH NEOPLASMS;

EID: 84918556188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115004     Document Type: Article

References (54)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371: 1695-1709.
2. Belcher R, Hayes K, Fedewa S, Chen AY (2014) Current treatment of head and neck squamous cell cancer. J Surg Oncol.
3. Mydlarz WK, Hennessey PT, Califano JA (2010) Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn 4: 53-65.
4. da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, et al. (2011) Advances and applications of oral cancer basic research. Oral Oncol 47: 783-791.
5. Pereira MC, Oliveira DT, Landman G, Kowalski LP (2007) Histologic subtypes of oral squamous cell carcinoma: prognostic relevance. J Can Dent Assoc 73: 339-344.
6. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82: 539-548.
7. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, et al. (2012) The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 11: M111 014647.
8. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, et al. (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277: 3890-3903.
9. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277: 3904-3923.
10. Iozzo RV, Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15: 1013-1031.
11. Edwards IJ (2012) Proteoglycans in prostate cancer. Nat Rev Urol 9: 196-206.
12. Tatrai P, Dudas J, Batmunkh E, Mathe M, Zalatnai A, et al. (2006) Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab Invest 86: 1149-1160.
13. Mundhenke C, Meyer K, Drew S, Friedl A (2002) Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 160: 185-194.
14. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, et al. (1998) Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102: 1599-1608.
15. Savore C, Zhang C, Muir C, Liu R, Wyrwa J, et al. (2005) Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 22: 377-390.
16. Iozzo RV, Cohen IR, Grassel S, Murdoch AD (1994) The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302 (Pt 3): 625-639.
17. Noonan DM, Fulle A, Valente P, Cai S, Horigan E, et al. (1991) The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266: 22939-22947.
18. Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV (1994) Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42: 239-249.
19. Mishra M, Chandavarkar V, Naik VV, Kale AD (2013) An immunohistochemical study of basement membrane heparan sulfate proteoglycan (perlecan) in oral epithelial dysplasia and squamous cell carcinoma. J Oral Maxillofac Pathol 17: 31-35.
20. Ida-Yonemochi H, Ikarashi T, Nagata M, Hoshina H, Takagi R, et al. (2002) The basement membrane-type heparan sulfate proteoglycan (perlecan) in ameloblastomas: its intercellular localization in stellate reticulum-like foci and biosynthesis by tumor cells in culture. Virchows Arch 441: 165-173.
21. Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T (2004) Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 33: 87-95.
22. Iozzo RV, Zoeller JJ, Nystrom A (2009) Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol Cells 27: 503-513.
23. Winzen U, Cole GJ, Halfter W (2003) Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters. J Biol Chem 278: 30106-30114.
24. Somoracz A, Tatrai P, Horvath G, Kiss A, Kupcsulik P, et al. (2010) Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol 41: 1310-1319.
25. Batmunkh E, Tatrai P, Szabo E, Lodi C, Holczbauer A, et al. (2007) Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Hum Pathol 38: 1508-1515.
26. Agostini M, Almeida LY, Bastos DC, Ortega RM, Moreira FS, et al. (2014) The Fatty Acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. Mol Cancer Ther 13: 585-595.
27. Aragao AZ, Belloni M, Simabuco FM, Zanetti MR, Yokoo S, et al. (2012) Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration. PLoS One 7: e43521.
28. Silva H, Frezard F, Peterson EJ, Kabolizadeh P, Ryan JJ, et al. (2012) Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: differential cellular accumulation mechanisms for platinum. Mol Pharm 9: 1795-1802.
29. Terp MG, Lund RR, Jensen ON, Leth-Larsen R, Ditzel HJ (2012) Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Cancer Genomics Proteomics 9: 265-273.
30. Noguti J, De Moura CF, De Jesus GP, Da Silva VH, Hossaka TA, et al. (2012) Metastasis from oral cancer: an overview. Cancer Genomics Proteomics 9: 329-335.
31. O'Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, et al. (2005) Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24: 1244-1251.
32. Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, et al. (2011) Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res 10: 4935-4947.
33. Chai YD, Zhang L, Yang Y, Su T, Charugundla P, et al. (2014) Discovery of potential serum protein biomarkers for lymph-node metastasis in oral cancer. Head Neck.
34. Feller L LJ (2012) Oral Squamous Cell Carcinoma: Epidemiology, Clinical Presentation and Treatment. Journal of Cancer Therapy 3: 263-268.
35. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, et al. (2012) Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 279: 1177-1197.
36. Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542.
37. Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341-347.
38. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, et al. (2002) Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 99: 10031-10036.
39. Pantazaka E, Papadimitriou E (2014) Chondroitin sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration. Biochim Biophys Acta 1840: 2643-2650.
40. Cattaruzza S, Perris R (2005) Proteoglycan control of cell movement during wound healing and cancer spreading. Matrix Biol 24: 400-417.
41. Zhou Z, Wang J, Cao R, Morita H, Soininen R, et al. (2004) Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 64: 4699-4702.
42. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, et al. (1999) Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 18: 163-178.
43. Klein G, Conzelmann S, Beck S, Timpl R, Muller CA (1995) Perlecan in human bone marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol 14: 457-465.
44. Bix G, Iozzo RV (2005) Matrix revolutions: "tail" of basement-membrane components with angiostatic functions. Trends Cell Biol 15: 52-60.
45. Hayashi K, Madri JA, Yurchenco PD (1992) Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol 119: 945-959.
46. Martin PT, Sanes JR (1997) Integrins mediate adhesion to agrin and modulate agrin signaling. Development 124: 3909-3917.
47. Yip GW, Smollich M, Gotte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5: 2139-2148.
48. Zhang JS, Anraku M, Kadowaki D, Imai T, Suenaga A, et al. (2011) Spectroscopic studies of interactions of chondroitin sulfates with cisplatin. Carbohydr Res 346: 631-637.
49. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
50. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
51. Dasari S, Bernard Tchounwou P (2014) Cisplatin in Cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
52. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, et al. (2013) Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193.
53. Eberle KE, Sansing HA, Szaniszlo P, Resto VA, Berrier AL (2011) Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One 6: e21496.
54. Teng PN, Wang G, Hood BL, Conrads KA, Hamilton CA, et al. (2014) Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer 110: 123-132.